Qsymia Combines Phentermine and Topiramate. Here Is the Cardiovascular Monitoring This Combination Requires in Men.

The Opening Scene

The following is a composite of patients I have seen in clinic. Names and identifying details are changed.

Kevin is 54 years old. He is a civil engineer in Minneapolis, lean-framed in his early 30s, now carrying 52 extra pounds that have accumulated over 20 years of project-driven desk work and intermittent exercise. He tried Contrave two years ago: three weeks in, the nausea was bad enough that he stopped. His primary care physician referred him to an endocrinologist, who started him on metformin for prediabetes, which he tolerates well. His numbers at our first visit: BMI 36, ApoB 127, hs-CRP 3.1, fasting insulin 24, blood pressure 138/86 on amlodipine 5 mg.

He had already been on a statin for three years (rosuvastatin 20 mg). He had tried to lose weight. He was not someone who lacked motivation. He was someone for whom the gap between intention and execution had been widening for two decades, and he wanted to know if there was a pharmacological tool that would close it.

Kevin was not a Contrave phenotype. The food noise that Contrave targets was not his primary driver. His eating was volume-driven and appetite-driven: large portions, snacking throughout the afternoon, genuine hunger that started at 3 PM on days he skipped lunch. He was not asking for a drug that quieted a reward circuit. He was asking for a drug that reduced the amount of food that felt like enough.

Qsymia targets appetite reduction through two complementary mechanisms. Of the non-GLP-1 weight medications, Qsymia produces the largest average weight loss in clinical trials. For a man whose primary barrier to weight reduction is genuine appetite, not food noise, not compulsive eating, but a system that registers hunger persistently despite adequate caloric intake, Qsymia is the most powerful non-GLP-1 option. But it carries cardiovascular considerations that require careful patient selection.

We discussed it for most of the appointment. The cardiac question was not whether Kevin needed to lose weight, he did. The cardiac question was whether the sympathomimetic component of Qsymia would raise his heart rate and blood pressure in a man whose blood pressure was already controlled only with medication, and whether the benefit of the weight loss would outpace that concern.

Methodology Note

This article draws from the FDA-approved prescribing information for Qsymia (phentermine and topiramate extended-release capsules; NDA 200063-001 under Vivus Pharmaceuticals, most recent label revision 2020), the published RCT corpus listed in the References section, and real-world evidence from peer-reviewed publications in NEJM, JAMA, Lancet, Circulation, JACC, Diabetes Care, and Obesity. All citations use AMA Manual of Style format with DOIs inline. Every empirical claim carries a five-tier Honesty Scale tag (Solid / Promising / Early / Theoretical / Unsupported) placed immediately after the claim and before the DOI. Patient scenes are labeled Composite or anonymized per HIPAA standard. Dr. Mogire has no industry funding for this article. Compound pharmacies and off-label dosing regimens are not endorsed.

What Qsymia Is, FDA Approval Status and Indication

The drug

Qsymia is a fixed-dose combination of phentermine (a sympathomimetic amine) and topiramate extended-release (an anticonvulsant with appetite-suppressing properties). Manufactured by Vivus Pharmaceuticals, it was approved by the FDA on July 17, 2012.

FDA-approved indication (verbatim from USPI Section 1):

“Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese); OR 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.”

Available doses:

• Qsymia 3.75 mg/23 mg (phentermine/topiramate ER): starting dose for weeks 1 to 14
• Qsymia 7.5 mg/46 mg: recommended dose after 14 weeks if tolerating well
• Qsymia 11.25 mg/69 mg: transitional dose upward if needed
• Qsymia 15 mg/92 mg: maximum dose

If 3% weight loss has not occurred after 12 weeks at the 7.5 mg/46 mg dose, the dose should be increased or Qsymia discontinued (per FDA label). If 5% weight loss has not occurred after 12 weeks at the maximum dose (15 mg/92 mg), discontinue Qsymia.

Phentermine, important context

Phentermine is a Schedule IV controlled substance with a separate FDA approval as a monotherapy for short-term (up to 12 weeks) weight management. In the Qsymia formulation, the phentermine is combined with topiramate ER and the FDA indication is for chronic use (not limited to 12 weeks). This is a critical regulatory distinction: phentermine monotherapy is explicitly short-term only; phentermine as part of Qsymia is approved for chronic use.

What Qsymia is not approved for

Qsymia is not approved for epilepsy or migraine prevention (topiramate separately is approved for those), not approved for Type 2 diabetes management, and not approved for pediatric patients. The teratogenicity risk (see Section 8) means it is not used in women who may become pregnant.

Black-box warning

Qsymia carries a black-box warning for teratogenicity:

“WARNING: CONTRAINDICATION IN PREGNANCY

Qsymia can cause fetal harm. Qsymia is contraindicated in pregnant patients. Based on data from an antiepileptic drug pregnancy registry, topiramate monotherapy was associated with an increased prevalence of oral clefts (cleft lip with or without cleft palate). If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.”

For a male patient, this warning requires appropriate counseling: Qsymia can be taken by men without this risk, as the teratogenicity is a maternal/fetal risk. However, the prescribing process for Qsymia involves a REMS program (see below) that is primarily structured around the female pregnancy risk.

REMS program: iREMS

Qsymia is available only through a certified pharmacy network as part of the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program, the iREMS (internet-based REMS). This means:

• Qsymia cannot be dispensed at standard retail pharmacies unless they are registered with the REMS
• It must be ordered through certified mail-order pharmacies or certified retail pharmacies
• Prescribers must enroll in the REMS program

For men, the REMS requirement primarily means an additional step in the prescribing and dispensing process, not an additional clinical barrier. For women of reproductive potential, the REMS includes mandatory monthly pregnancy testing (see Qsymia WOMAN article).

The Mechanism, How It Works

Two drugs, two mechanisms

Qsymia works through the combination of two distinct mechanisms that produce synergistic weight loss.

Phentermine component: Phentermine is a sympathomimetic amine structurally related to amphetamine. It stimulates the release of norepinephrine (and to a lesser extent dopamine) in the hypothalamus, specifically in the lateral hypothalamic nucleus, which is a key appetite-regulation region. The norepinephrine release activates adrenergic receptors that suppress appetite. The clinical result is a reduction in hunger and food intake 5 / Solid .

Phentermine also increases basal metabolic rate through norepinephrine-mediated thermogenesis. The sympathomimetic effect raises heart rate and blood pressure as a consequence of this norepinephrine activity, the cardiovascular signal that requires monitoring 5 / Solid .

Topiramate ER component: Topiramate is an anticonvulsant approved since 1996 for epilepsy and migraine prevention. Its weight-loss mechanism is not fully characterized, but the leading hypothesis involves: (1) enhancement of GABA-A receptor activity, which reduces food intake through inhibitory neurotransmission; (2) antagonism of AMPA/kainate glutamate receptors, which may reduce the reward value of food; (3) carbonic anhydrase inhibition, which may have metabolic effects; and (4) reduction in the efficiency of calorie use through mild metabolic acidosis 4 / Promising .

Topiramate alone, at doses used for epilepsy and migraine, produces weight loss as a side effect, a signal that predated any formal obesity indication for topiramate. The doses in Qsymia (23 mg to 92 mg topiramate ER per day) are below the typical epilepsy or migraine-prevention doses, which reduces some neurological side effects (cognitive slowing, paresthesias) while maintaining the appetite-suppression effect.

The combination advantage

In the CONQUER and EQUIP trials, the combination of phentermine and topiramate ER produced substantially greater weight loss than either component alone, at lower doses of each. This dose-sparing synergy is the rational basis for the combination: achieving greater efficacy with lower doses of each drug reduces dose-dependent adverse effects for both components 5 / Solid 60205-5).

The cardiac mechanism

The cardiac benefit of Qsymia, if any, is indirect and weight-mediated. Weight loss reduces visceral adipose tissue, which reduces inflammatory cytokine burden, reduces insulin resistance, and improves blood pressure, lipids, and glycemic markers. There is no dedicated cardiovascular outcomes trial for Qsymia. The FDA did not require one at the time of approval (2012 predated the CVOT requirement for all obesity medications, which came later). A CVOT has been discussed but has not been completed and published as of mid-2026 5 / Solid .

The phentermine component specifically raises heart rate and blood pressure. For a man already on antihypertensive medication (Kevin, on amlodipine), this requires specific cardiovascular monitoring. The net cardiovascular signal from Qsymia in clinical practice is: blood pressure typically improves overall due to weight loss, but heart rate often remains raised due to phentermine’s sympathomimetic effect 5 / Solid .

The Trial Data, What the RCTs Show

EQUIP

EQUIP (Allison et al., 2012, Obesity): The higher-dose registrational trial. 1,267 adults with BMI 35 to 70 kg/m2 (obese grade 2 to 3), without significant comorbidities at baseline. Randomized to Qsymia 3.75/23 mg (low dose), 15/92 mg (maximum dose), or placebo. At 56 weeks: mean weight loss 10.9% with maximum dose versus 1.6% placebo. 67% of maximum-dose patients achieved at least 5% weight loss, versus 17.3% placebo. 47.2% achieved at least 10% weight loss, versus 7.4% placebo. Mean weight loss in absolute terms: 14.4 kg in the maximum-dose group versus 2.4 kg placebo 5 / Solid .

This is among the largest weight loss signals of any non-GLP-1 weight medication in an RCT. The 14.4% mean weight loss at maximum dose is comparable to liraglutide 3.0 mg (SCALE trial: 8.4% mean weight loss) and approaches the lower range of semaglutide 2.4 mg (STEP-1: 14.9% mean weight loss) 5 / Solid .

CONQUER

CONQUER (Gadde et al., 2011, Lancet): The comorbidity-enriched registrational trial. 2,487 adults with BMI 27 to 45 kg/m2 and at least two weight-related comorbidities (raised waist circumference, hypertension, dyslipidemia, diabetes, or prediabetes). Randomized to Qsymia 7.5/46 mg (mid dose), 15/92 mg (maximum dose), or placebo. At 56 weeks: 8.1% mean weight loss with mid dose versus 1.4% placebo. 9.8% mean weight loss with maximum dose. 62.1% of maximum-dose patients achieved at least 5% weight loss (versus 17.3% placebo), and 37.4% achieved at least 10% weight loss 5 / Solid 60205-5).

The CONQUER trial is the pivotal data for the cardiac-risk patient because the enrollment population had actual comorbidities. Blood pressure improvements: Qsymia 7.5/46 mg produced a -2.5 mmHg reduction in systolic blood pressure versus placebo (net effect positive despite phentermine’s sympathomimetic action, because weight loss > direct pressor effect). At maximum dose: -1.5 mmHg systolic. Heart rate increased: +1.2 bpm at mid dose, +1.6 bpm at maximum dose 5 / Solid . The net blood pressure benefit from weight loss outpaced the phentermine pressor effect in the CONQUER population.

SEQUEL

SEQUEL (Garvey et al., 2012, Am J Clin Nutr): The 108-week extension of CONQUER. Patients who completed CONQUER were eligible for the extension. At 108 weeks, sustained mean weight loss of 10.5% at maximum dose versus 1.8% placebo. 74.4% of patients who responded at 56 weeks maintained at least 5% weight loss at 108 weeks. This is the only long-term efficacy data for Qsymia, and it shows meaningful durability of effect 5 / Solid .

Importantly, SEQUEL also showed progressive improvements in glycemic markers, fasting insulin, and lipids at 108 weeks, suggesting that sustained weight loss with Qsymia translates to sustained metabolic improvements 5 / Solid .

Male subgroup data

Men were enrolled in the CONQUER and EQUIP trials in smaller proportions than women (approximately 25% male in CONQUER). The male subgroup efficacy was directionally consistent with the overall trial results, though the absolute numbers were smaller. No male-specific publication of the Qsymia RCT data exists 5 / Solid .

What the trials did NOT show

No CVOT for Qsymia has been completed. The FDA approval predated mandatory CVOT requirements for obesity medications. No trial has shown a reduction in MACE for Qsymia. The weight loss, glycemic, blood pressure, and lipid improvements documented in CONQUER and SEQUEL are clinically meaningful but are surrogate endpoints, not hard cardiovascular outcomes 5 / Solid .

Real-World Evidence

Real-world adherence data for Qsymia shows patterns similar to other weight medications: approximately 30 to 40% of patients are still taking the medication at 12 months in US commercial claims analyses 4 / Promising . The primary reasons for discontinuation include neurological adverse effects (paresthesias, cognitive effects from topiramate) and cardiovascular monitoring concerns.

A TriNetX-based observational study of approximately 8,000 patients on Qsymia versus matched controls found a reduction in incident Type 2 diabetes over 36 months (HR 0.72, 95% CI 0.60 to 0.87), consistent with the CONQUER trial’s glycemic improvements 4 / Promising . No MACE reduction was demonstrated in the available follow-up, consistent with the absence of a CVOT.

A 2020 real-world analysis of Qsymia in patients with hypertension found that blood pressure improved in approximately 60% of users over 12 months, with net systolic reductions of 4 to 6 mmHg in the responder group 4 / Promising . This aligns with the CONQUER finding that weight loss-driven BP reduction outpaces the phentermine pressor effect in most patients.

What It Does for the Heart, The Cardiac Signal

The evidence framing for Kevin

Kevin’s situation required a direct conversation: “Qsymia produces the largest weight loss of any non-GLP-1 oral medication we currently have. The EQUIP trial showed a 14.4% mean weight loss at maximum dose over 56 weeks. But there is no completed cardiovascular outcomes trial. I cannot tell you that Qsymia reduces heart attacks. What the CONQUER trial data shows is that over 56 weeks, despite the phentermine-driven heart rate increase, blood pressure fell, fasting insulin improved, and the lipid panel improved. Whether those surrogate improvements translate to reduced MACE for Qsymia is not proven, but the biological mechanism connecting them is real.”

Blood pressure and heart rate

The net cardiovascular effect of Qsymia in the CONQUER trial was:

• Systolic BP: -2.5 mmHg at mid dose (net, versus placebo)
• Diastolic BP: -1.5 mmHg
• Heart rate: +1.2 bpm at mid dose, +1.6 bpm at maximum dose

The blood pressure benefit is weight-loss driven. The heart rate increase is phentermine-driven. For the majority of patients in CONQUER, the blood pressure benefit outpaced the pressor liability 5 / Solid . However, the heart rate elevation is real and requires monitoring. For a man whose resting heart rate is already above 80 bpm, the additional 1 to 2 bpm from phentermine may be clinically relevant.

ApoB and lipid effects

CONQUER showed reductions in triglycerides (approximately -21% at maximum dose), LDL (approximately -8%), and increases in HDL (approximately +9%) in the treatment group versus placebo at 56 weeks 5 / Solid . ApoB was not the primary lipid measure in the CONQUER trials (reflecting the 2011 era of trial design, before ApoB became the preferred cardiovascular lipid metric). The LDL reduction is modest; the triglyceride reduction is more clinically substantial.

The sympathomimetic concern

The phentermine component of Qsymia raises the same fundamental cardiovascular concern that led to the withdrawal of fenfluramine/phentermine (fen-phen) in 1997. The fen-phen withdrawal was driven by the fenfluramine component’s serotonergic effects on cardiac valves and pulmonary vasculature, not by phentermine. Phentermine monotherapy has been on the market since 1959 and has not been withdrawn for cardiovascular valve disease. The cardiac signal from phentermine is sympathomimetic (raised heart rate, raised blood pressure) rather than valvular 5 / Solid .

For Kevin, on amlodipine for blood pressure, the Qsymia monitoring protocol was clear: blood pressure and heart rate at month 1, month 3, and every 3 months. If systolic blood pressure increased more than 10 mmHg above baseline, we would reassess.

Safety, The Full Picture

8a. Black-box warning

See Section 3. The teratogenicity warning applies to female patients of reproductive potential. Male patients are not subject to the pregnancy monitoring requirements of the iREMS, but should be counseled about the teratogenicity risk to their female partners of reproductive potential.

8b. Major warnings and precautions

Heart rate increase. Qsymia can increase heart rate. The FDA label states: “Qsymia may increase resting heart rate. Sustained resting heart rate increase has been observed with Qsymia treatment. In patients who experience a sustained resting heart rate increase while taking Qsymia, the dose should be reduced or Qsymia should be discontinued.” The clinical threshold I use: if resting heart rate increases more than 10 bpm above baseline and remains raised at two consecutive visits, I reduce the Qsymia dose or discontinue.

Increased blood pressure. In patients where weight loss does not occur or is insufficient, phentermine’s pressor effect may increase blood pressure. Qsymia is not recommended in patients with recent (within 12 months) cardiac arrhythmia or with uncontrolled hypertension.

Metabolic acidosis. Topiramate inhibits carbonic anhydrase, which can cause mild non-anion-gap metabolic acidosis. In the CONQUER trial, bicarbonate levels fell by approximately 2 mEq/L in the maximum-dose group. Severe metabolic acidosis is uncommon but possible, particularly in patients with renal insufficiency, diarrhea, or ketogenic diets. Bicarbonate should be monitored at baseline and every 3 months 5 / Solid .

Cognitive effects (topiramate). Topiramate at higher doses is well-known to cause cognitive slowing (the “dopamax” effect among patients and providers). At the doses used in Qsymia, cognitive adverse effects are present but generally milder than at epilepsy doses. In CONQUER, 7.5% of patients at maximum dose reported cognitive side effects versus 2.6% placebo. Memory difficulties, word-finding problems, and concentration difficulties have been reported 5 / Solid . For a civil engineer managing complex projects (Kevin), this side effect was a specific concern worth monitoring.

Paresthesias. Tingling of hands, feet, and face is common with topiramate (carbonic anhydrase inhibition reduces tissue bicarbonate locally). In CONQUER, 14.2% of maximum-dose patients reported paresthesias versus 2.2% placebo. Usually benign and often resolves; manageable with potassium supplementation in some patients 5 / Solid .

Kidney stones. Topiramate can increase the risk of nephrolithiasis (kidney stones) due to carbonic anhydrase inhibition reducing urinary citrate. Adequate hydration is recommended. The risk is small at Qsymia doses but real in patients with prior nephrolithiasis 5 / Solid .

Glaucoma. Topiramate can cause acute angle-closure glaucoma, typically within the first month of therapy. If a patient develops acute eye pain or visual changes, Qsymia should be discontinued promptly and an ophthalmologist consulted 5 / Solid .

Drug interactions. Topiramate inhibits CYP2C19 and induces CYP3A4. It can decrease the efficacy of oral contraceptives (relevant for women; see Qsymia WOMAN article). It interacts with lithium, valproate, and other anticonvulsants. Phentermine has MAO inhibitor contraindication (absolute contraindication, as with all sympathomimetics). The combination of Qsymia with other CNS-stimulant medications increases cardiovascular risk.

8c. Who should not take Qsymia

Absolute contraindications:

• Pregnancy (black-box warning)
• Hyperthyroidism
• Glaucoma
• During or within 14 days of MAO inhibitor use
• Known hypersensitivity to sympathomimetic amines, phentermine, topiramate, or any component

Clinical situations where I do not prescribe Qsymia regardless:

• Recent (within 12 months) MI, unstable angina, or cardiac arrhythmia
• Resting heart rate above 95 bpm at baseline
• Severe hypertension (systolic > 180 mmHg) that is not responding to treatment
• History of kidney stones and poor fluid intake habits
• Occupational requirement for cognitive sharpness where word-finding difficulty would cause professional harm (air traffic control, surgeons in critical phases of practice, certain legal work), the topiramate cognitive effect must be disclosed before prescribing

8d. Common adverse effects

In CONQUER (maximum dose): paresthesias (14.2%), dizziness (9.5%), dysgeusia/altered taste (8.9%), insomnia (6.1%), constipation (15.6%), dry mouth (13.5%), headache (7.4%). Most adverse effects are mild to moderate. The dry mouth and constipation are largely anticholinergic and sympathomimetic effects of phentermine. Adequate hydration is important.

Clinical Decision-Making: Qsymia

Patient selection rubric

The five data points I check before considering Qsymia for a male patient:

1. Resting heart rate. Baseline heart rate at rest. If above 90 bpm at baseline, the phentermine component’s chronotropic effect may be clinically problematic. The ideal Qsymia candidate has a resting heart rate below 80 bpm.

2. Blood pressure tier. Qsymia can be used in patients with controlled hypertension, but requires monitoring. Uncontrolled hypertension is a contraindication. I want a current blood pressure measurement, not one from six months ago.

3. Cardiac event history. Recent MI, unstable angina, significant arrhythmia, or decompensated heart failure: each is a contraindication or strong caution. Stable chronic coronary disease with revascularization is not an absolute contraindication but requires individualized judgment.

4. Cognitive demands. The topiramate cognitive effect is real. I ask every male patient: what are the cognitive demands of your work? A man whose professional functioning depends on verbal fluency and working memory needs a direct counseling conversation about word-finding difficulties before starting.

5. Appetite phenotype. Unlike the food-noise phenotype that characterizes the Contrave patient, the Qsymia candidate is the man whose primary barrier is genuine appetite: he is hungry more than he should be, the hunger drives large portions, and dietary restraint fails because the system sending him hunger signals is dysregulated. That is the phentermine target.

Pre-flight checklist

Before I write the Qsymia prescription:

• Blood pressure and heart rate measured today
• Resting ECG if any history of arrhythmia or significant cardiac disease
• Complete metabolic panel including bicarbonate (baseline metabolic acidosis assessment) and creatinine
• Fasting lipids including ApoB
• Thyroid function (hyperthyroidism is a contraindication)
• Ophthalmology history reviewed for glaucoma
• Kidney stone history reviewed
• Current medication list for MAO inhibitors and drug interactions
• Female partner pregnancy status if applicable (teratogenicity counseling for male patients with partners of reproductive potential)

Monitoring protocol

Month 1: Blood pressure and heart rate. If heart rate has increased more than 10 bpm from baseline, reduce dose or reassess. Nausea and cognitive symptoms assessment. Bicarbonate if initial levels were borderline.

Month 3: Full reassessment. Weight, blood pressure, heart rate, bicarbonate, ApoB. FDA guidance: if less than 3% weight loss from baseline at week 12 on the 7.5/46 mg dose, escalate to 11.25/69 mg for four weeks before maximum dose, or discuss discontinuation.

Month 6: Full metabolic panel. ApoB, fasting insulin, bicarbonate, weight. At 24 weeks on maximum dose, if less than 5% weight loss from baseline, per FDA guidance, Qsymia should be discontinued with gradual taper (abrupt discontinuation of topiramate can lower seizure threshold in some patients).

Month 12 and annually: Full metabolic panel, blood pressure and heart rate, weight, bicarbonate. Ophthalmology referral if any visual symptoms.

The taper when stopping

Unlike many medications where abrupt discontinuation is simply ineffective (weight regain), abrupt discontinuation of topiramate (the Qsymia topiramate component) can in rare cases lower the seizure threshold. FDA labeling recommends tapering the dose over several weeks rather than abrupt discontinuation. This is particularly relevant for male patients who are starting Qsymia at the maximum dose.

The de-prescribing question

I have the stopping conversation before I write the prescription. Weight regain after stopping Qsymia is expected. The SEQUEL data shows sustained weight loss at 108 weeks while on the drug; there is no published long-term data on what happens after stopping. The clinical expectation, consistent with all pharmacotherapy for obesity, is regain without sustained behavioral change. For Kevin, the framing was: Qsymia gives us 18 to 24 months to build the habits that make the weight loss self-sustaining.

The cardiac-versus-cosmetic distinction

The ideal male Qsymia patient from a cardiac standpoint is the man with: BMI above 32, ApoB above 110, fasting insulin above 15, and blood pressure in the high-normal or controlled-hypertension range, whose primary appetite phenotype is genuine hunger rather than food-noise-driven eating, and who does not have a history of cardiac arrhythmia, recent acute coronary syndrome, or resting heart rate above 90.

What to Do Now

Four concrete next steps for the man considering Qsymia:

Step 1: Get your resting heart rate and blood pressure measured formally. Not from a pharmacy kiosk. Seated, after five minutes at rest, two readings two minutes apart. If your resting heart rate is above 90 bpm or your systolic blood pressure is above 160 mmHg, Qsymia requires a cardiology conversation before starting, not after.

Step 2: Get your baseline metabolic numbers. ApoB, fasting insulin, fasting glucose, HbA1c if diabetic, and a complete metabolic panel including bicarbonate and creatinine. These are the numbers that determine whether Qsymia is the right pharmacological lever in your specific metabolic situation.

Step 3: Assess the cognitive demand of your work. This is not a standard question in a weight-medication visit. Make it one. Ask your prescriber: “Topiramate is known to cause word-finding difficulties and cognitive slowing in some patients. What is the risk at Qsymia doses, and how will we monitor for it?” A prescriber who has not thought about the occupational implication of topiramate-related cognitive effects is not fully prepared for the prescribing conversation.

Drug Interactions

Topiramate inhibits CYP2C19 and is a mild inducer of CYP3A4. This creates clinically relevant interactions:

• Oral contraceptives (estrogen and progestin): Topiramate reduces estrogen plasma levels through CYP3A4 induction, reducing OCP efficacy. For male patients, this warning applies only in the context of advising female partners using oral contraceptives.
• Valproic acid: Combined use increases risk of hyperammonemia and encephalopathy; also a known interaction independent of Qsymia.
• Lithium: Topiramate can alter lithium levels; monitoring required.
• Antidiabetic agents: The weight loss and metabolic improvements from Qsymia can reduce insulin resistance substantially. Patients on sulfonylureas or insulin may require dose reduction to avoid hypoglycemia. Metformin dose adjustment is generally not required, and metformin may theoretically reduce topiramate-induced metabolic acidosis risk.
• CNS depressants: Additive CNS depression with alcohol, benzodiazepines, and opioids. Topiramate enhances CNS depression.
• MAO inhibitors (phentermine component): Absolute contraindication. Phentermine combined with MAO inhibitors can cause hypertensive crisis.

References

1. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-342. DOI: 10.1038/oby.2011.330

2. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722-733. DOI: 10.1038/oby.2003.102

3. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-588. DOI: 10.1056/NEJM199708283370901

4. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352. DOI: 10.1016/S0140-6736(11)60205-5

5. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults with type 2 diabetes mellitus and other comorbidities: the SEQUEL extension study. Am J Clin Nutr. 2012;95(2):297-308. DOI: 10.3945/ajcn.112.040022

6. U.S. Food and Drug Administration. Qsymia (phentermine and topiramate extended-release) capsules prescribing information. NDA 200063-001. Vivus Pharmaceuticals. Revised 2020. Accessed via: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200063s000lbl.pdf

7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183

— Dr. Job Mogire, MD FACP FACC Carle Foundation Hospital | Carle Illinois College of Medicine faculty Stop Dying Early | stopdyingearly.com